AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth

Abbvie (ABBV) announced an update on their ongoing clinical study.

AbbVie (ABBV) has completed a post-marketing study in Korea called “Post-marketing Surveillance to Evaluate the Safety and Effectiveness of Upadacitinib in Korean Patients.” The study tracked real-world side effects and symptom changes in several immune-driven diseases, which helps support long-term use and can guide label and market strategy.

The treatment is upadacitinib, sold as Rinvoq, an oral pill that targets the JAK pathway. It is already approved for moderate to severe rheumatoid arthritis, atopic dermatitis, ankylosing spondylitis, and psoriatic arthritis, and this study checks how well it works and how safe it is in everyday Korean practice.

The study used an observational, cohort design with no random assignment or placebo control. Doctors prescribed Rinvoq as usual, and patients were followed prospectively, so results reflect routine clinical care rather than a tightly controlled trial setting.

The trial began after first submission on 2020-08-31, with patients followed for about 28 weeks to capture early safety and effectiveness signals. It is now listed as completed, and the record was last updated on 2026-02-10, showing AbbVie is still curating real-world data even without formal results posted yet.

For investors, a completed, updated Korean safety study should support confidence in Rinvoq’s durability across multiple indications and geographies. Positive real-world tolerability could help defend share against other JAK drugs and biologics, reduce regulatory risk, and support AbbVie’s long-term immunology revenue story in the face of biosimilar pressure.

This AbbVie post-marketing study of Rinvoq in Korea is completed and recently updated, with further details available on the ClinicalTrials portal.

To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.